News | EP Mapping and Imaging Systems | October 15, 2019

Kardium Announces Successful Results From GLOBAL-AF Study

Patients treated with Globe electrophysiology mapping and ablation solution showed 76 percent freedom from atrial fibrillation at 12 months after single treatment

Kardium Announces Successful Results From GLOBAL-AF Study

October 15, 2019 — Kardium Inc. announced that the Globe mapping and ablation system has successfully demonstrated safety and efficacy in the GLOBAL-AF study. The results of the study were published in the Journal of Cardiovascular Electrophysiology.[1] The study demonstrated a 76 percent percent freedom from atrial fibrillation at 12 months after a single treatment with the Globe system.

“I am very excited about the results from this first clinical experience with the Globe system” said Prof. Hans Kottkamp, head of electrophysiology, Sana Hospitals, Düsseldorf, Germany, the principal investigator. “The Globe system has demonstrated the ability to provide rapid and effective pulmonary vein isolation. In addition, the ability to perform high-resolution mapping and ablation of the atrium will deliver a unique and comprehensive treatment for patients that has the potential to further improve outcomes and advance new strategies for the treatment of AF.”

The Globe system is a mapping and ablation solution that consists of a catheter with 122 electrodes and advanced software, that together enable rapid pulmonary vein isolation, high-resolution mapping and the ability to ablate anywhere in the atrium, all with a single catheter.

Atrial fibrillation is the most common heart rhythm disorder and affects about 33 million people worldwide. It can increase the risk of stroke by up to five times.

The GLOBAL-AF study is a prospective multicenter study that evaluated the safety and effectiveness of the system in 60 patients at two centers in Europe. Patients were assessed for atrial fibrillation with seven-day continuous Holter monitoring at discharge and then 3, 6 and 12 months after the treatment. Patients in the efficacy cohort had 100 percent pulmonary vein isolation and 76 percent freedom from atrial fibrillation at 12 months, off antiarrhythmic drugs, after a single procedure.

For more information: www.kardium.com

Reference

1. Kottkamp H., Hindricks G., Ponisch C., et al. Global multielectrode contact‐mapping plus ablation with a single catheter in patients with atrial fibrillation: Global AF study. Journal of Cardiovascular Electrophysiology, published online Sept. 11, 2019. https://doi.org/10.1111/jce.14172

Related Content

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

News | Atrial Fibrillation | August 04, 2020
August 4, 2020 — Abbott announced the first enrollments in the TactiFlex PAF  investigational device exemption (IDE)
PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the
Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking
Contact Force Sensing Catheter Improved Outcomes in Persistent Atrial Fibrillation Ablation. #HRS2020 #heartrhythm2020
News | Atrial Fibrillation | May 13, 2020
May 13, 2020 — The PRECEPT study testing the use of the Biosense Webster Thermocool Smarttouch SF Catheter for the tr
The Swiss-AF study shows High Incidence Of Silent Brain Infarcts Found in Anticoagulated Atrial Fibrillation Patients. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 – A new clinical study found that patients with...
PINNACLE FLX Study of New Watchman FLX LAA Occluder Meets Safety and Efficacy Endpoints. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — Positive 12-month results were announced today from the...
The first-in-human results show positive results for Medtronic's pulsed field ablation in safety and efficiency. #Heartrhythm2020 #HRS2020 #HRS20
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — New clinical trial reveals the first-in-human results for paroxysmal or persistent atrial fibrillation
POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation  (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020
News | Atrial Fibrillation | March 29, 2020
March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing transcath
Medtronic's PulseSelect Pulsed Field Ablation (PFA) System

Medtronic's PulseSelect Pulsed Field Ablation (PFA) System.

News | Atrial Fibrillation | January 31, 2020
January 31, 2020 – The U.S.
Frequent Drinking Greater Risk Factor for Heart Rhythm Disorder Than Binge Drinking

Image courtesy of the American Heart Association.

News | Atrial Fibrillation | October 22, 2019
October 22, 2019 —  Drinking small amounts of alcohol frequently is linked with a higher likelihood of...